STOCK TITAN

Virios Therapeutics, Inc. SEC Filings

VIRI NASDAQ

Welcome to our dedicated page for Virios Therapeutics SEC filings (Ticker: VIRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Searching for the latest developments on Virios Therapeutics’ antiviral pipeline often starts with a single question: where in hundreds of SEC pages can I find the numbers and study updates that move the stock? On this page you’ll locate every Virios Therapeutics SEC filing explained simply, from the annual report 10-K that breaks down R&D spend to the 8-K material events explained when new clinical data emerges.

Our AI-powered summaries strip out jargon so understanding Virios Therapeutics SEC documents with AI feels natural. Need fast access to a Virios Therapeutics quarterly earnings report 10-Q filing? We highlight cash runway, trial costs, and variance from previous quarters. Tracking leadership confidence? Real-time alerts surface Virios Therapeutics Form 4 insider transactions the moment they hit EDGAR, letting you spot Virios Therapeutics executive stock transactions Form 4 before the market digests them.

Use cases professionals rely on include:

  • Compare R&D burn across quarters with one-click Virios Therapeutics earnings report filing analysis.
  • Review Virios Therapeutics proxy statement executive compensation to gauge alignment with shareholders.
  • Dive into shelf registrations to understand dilution risk without wading through legal text.

Whether you’re assessing phase-two trial momentum or monitoring a Virios Therapeutics insider trading Form 4 transactions cluster, Stock Titan delivers comprehensive coverage: every 10-K, 10-Q, 8-K, S-1, and more, updated in real time. Investors, analysts, and healthcare professionals save hours while our expert analysis links each disclosure to the science that underpins Virios Therapeutics’ potential.

Rhea-AI Summary

Dogwood Therapeutics, Inc. (VIRI) filed a Form S-8 to register 108,612 additional shares of common stock for issuance under its Amended and Restated 2020 Equity Incentive Plan. The new shares supplement prior S-8 registrations (Dec 21 2020 and Jun 22 2022) and follow Board authorization on Apr 17 2025 and shareholder approval on Jun 18 2025. Standard incorporation-by-reference, exhibits (legal opinion, auditor consent, plan document) and undertakings are included. The filing is an administrative step to ensure sufficient shares are available for employee equity awards and does not provide new financial results or strategic disclosures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Summary

Dogwood Therapeutics held its Annual Meeting on June 18, 2025, where stockholders approved several key matters. The most significant development was the approval of Amendment No. 2 to the company's Equity Incentive Plan, which increased the share reserve by 108,612 shares to a total of 191,112 shares. This follows the company's 25-for-1 reverse stock split from October 2024.

At the meeting, which had a 48.22% quorum representing 921,595 shares, stockholders voted on three main items:

  • Election of seven directors, including Abel De La Rosa, Greg Duncan, and other board members, all of whom were successfully elected
  • Ratification of Forvis Mazars, LLP as independent auditor for FY2025, approved with 888,808 votes in favor
  • Approval of the Equity Incentive Plan amendment, which passed with 275,020 votes in favor

The filing indicates Dogwood Therapeutics is an emerging growth company trading on the Nasdaq Capital Market under symbol DWTX.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Dogwood Therapeutics, Inc. (DWTX) filed a low-complexity Form 4 reporting insider activity by director Abel De La Rosa on 06/18/2025. The filing shows two identical grants of 210 non-qualified stock options each, for a combined total of 420 options.

Key terms of the options:

  • Exercise price: $4.80 per share
  • Vesting/first exercisable date: 06/18/2026
  • Expiration date: 06/18/2035
  • Ownership form: Direct

No common shares were bought or sold and no other derivative transactions were reported. After the grants, De La Rosa’s beneficial ownership consists solely of the 420 options. The transaction is coded “A” (acquisition) and was filed on 06/23/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Virios Therapeutics (VIRI)?

The current stock price of Virios Therapeutics (VIRI) is $0.155 as of February 7, 2025.

What is the market cap of Virios Therapeutics (VIRI)?

The market cap of Virios Therapeutics (VIRI) is approximately 4.3M.

What is the core business of Virios Therapeutics, Inc.?

Virios Therapeutics is dedicated to developing novel therapeutic solutions through rigorous clinical research and a diversified pipeline of investigational drugs. Its focus lies in addressing significant unmet medical needs within the biopharmaceutical space.

How does Virios Therapeutics generate revenue?

The company primarily invests in clinical research and strategic partnerships to advance its therapeutic discoveries. Revenue generation is closely linked to leveraging collaborations and licensing opportunities as progress is made in clinical development.

What distinguishes Virios Therapeutics from its competitors?

The company differentiates itself through its robust, research-driven approach and diversified clinical-stage pipeline. Its emphasis on scientific rigor, strategic partnerships, and transparent methodology sets it apart in a competitive biopharmaceutical landscape.

What role does clinical research play in their operations?

Clinical research is at the heart of Virios Therapeutics' operations, driving both the development of its therapeutic candidates and ensuring that each project meets stringent regulatory standards. This rigorous research framework helps validate the efficacy and safety of its investigative drugs.

How does the company approach strategic partnerships?

Virios Therapeutics actively seeks strategic collaborations with research institutions and industry partners to bolster its clinical programs. These partnerships facilitate resource sharing and help mitigate risks while accelerating the development of its therapeutic pipeline.

What are the main challenges faced by companies in this sector?

Biopharmaceutical companies like Virios Therapeutics face challenges such as navigating complex regulatory requirements, managing clinical trial risks, and ensuring adequate investment in research. Their ability to overcome these challenges relies largely on scientific innovation and robust clinical methodologies.
Virios Therapeutics, Inc.

NASDAQ:VIRI

VIRI Rankings

VIRI Stock Data

4.30M
27.76M
1.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
ALPHARETTA